Michael J. Thorpy, MD, leads a discussion on the diagnosis of excessive daytime sleepiness and tools used to diagnose the condition, such as the Epworth Sleepiness Scale and multiple sleep latency test.
Alon Y. Avidan, MD, MPH, outlines the signs and symptoms of narcolepsy, including excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations, and insomnia, as well as the challenges in diagnosis.
Key opinion leaders discuss the 2 types of narcolepsy and the appropriateness of high-performance liquid chromatography analysis of cerebrospinal fluid for hypocretin-1 to confirm a diagnosis in certain patients.
Russell Rosenberg, PhD, DABSM, articulates the goals of therapy in treating narcolepsy, which include improving functioning, increasing safety of patients and others, and enhancing overall quality of life.
Eveline Honig, MD, MPH, highlights a variety of nonpharmacologic strategies for adults and children with narcolepsy, including a gluten-free diet, increased protein intake, short naps, and regular exercise.
Panelists discuss pitolisant for treatment of excessive daytime sleepiness associated with narcolepsy, including its unique mechanism of action that increases histamine in the brain, its once-daily dosing, and its classification as a nonscheduled medication.
Expert sleep specialists discuss solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy, including its novel mechanism of action as a dual-acting dopamine and norepinephrine reuptake inhibitor.
Sleep experts discuss unmet needs surrounding the treatment of narcolepsy, including the need for more medication options to give patients a choice and for medications that treat nonspecific symptoms and cognitive issues.
Panelists offer community physicians guidance on treating narcolepsy, emphasizing the need to consider narcolepsy in the differential diagnosis of patients who present with excessive daytime sleepiness.